Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

The Latest Breaking News from DGX

Quest Diagnostics Stock: Is Wall Street Bullish or Bearish?

While Quest Diagnostics has outpaced the broader market over the past year, Wall Street analysts maintain a cautiously optimistic outlook on the stock’s prospects.

Barchart

Quest Diagnostics's Q2 2026 Earnings: What to Expect

Quest Diagnostics is expected to unveil its second-quarter results later this month, and analysts expect a single-digit growth in earnings.

Barchart

Is Quest Diagnostics Stock Underperforming the S&P 500?

While Quest Diagnostics has lagged behind the S&P 500 Index over the past year, analysts are moderately optimistic about the stock’s prospects.

Barchart

From analysis to the latest developments in health,
read the most diverse news in one place.

Quest Diagnostics Stock: Analyst Estimates & Ratings

Quest Diagnostics is keeping analysts reasonably upbeat as steady execution and momentum continue supporting Wall Street confidence.

Barchart

Quest Diagnostics Earnings Preview: What to Expect

Quest Diagnostics is set to announce its first-quarter earnings next month, and Wall Street expects the company’s EPS to increase by a single digit.

Barchart

Is Henry Schein Stock Underperforming the S&P 500?

Henry Schein has trailed behind the S&P 500 Index, yet Wall Street analysts remain moderately optimistic about the stock’s prospects.

Barchart

How Is Quest Diagnostics’ Stock Performance Compared to Other Healthcare Stocks?

Quest Diagnostics has outpaced its healthcare peers over the past year, and analysts are maintaining a moderately positive outlook on its future performance.

Barchart

Read news from The Economist, FT, and more,
with one subscription

Do Wall Street Analysts Like Quest Diagnostics Stock?

Quest Diagnostics has outperformed the broader market over the past year, and analysts remain somewhat bullish about the stock’s prospects.

Barchart

The battle of the SuperPods: Nvidia challenges Huawei with Vera Rubin powered DGX cluster that can deliver 28.8 Exaflops with only 576 GPUs

Nvidia’s Rubin DGX SuperPOD delivers 28.8 Exaflops using 576 GPUs, combining compute, memory, and software to rival Huawei’s SuperPOD.

TechRadar

What You Need To Know Ahead of Quest Diagnostics' Earnings Release

Quest Diagnostics is expected to unveil its fourth-quarter results soon, and analysts expect a single-digit growth in earnings.

Barchart

How Is Henry Schein's Stock Performance Compared to Other Healthcare Stocks?

Despite Henry Schein’s underperformance relative to its peers, Wall Street analysts remain moderately optimistic about the stock’s prospects.

Barchart

Bio-Techne Stock: Is TECH Underperforming the Healthcare Sector?

Despite Bio-Techne’s weak performance relative to the healthcare sector over the past year, Wall Street analysts remain strongly optimistic about the stock’s prospects.

Barchart

Quest Diagnostics Stock: Is DGX Outperforming the Healthcare Sector?

Quest Diagnostics has outperformed the broader healthcare sector over the past year. Moreover, Wall Street analysts remain moderately optimistic about its prospects.

Barchart

How Is Labcorp Holdings' Stock Performance Compared to Other Healthcare Stocks?

Despite Labcorp Holdings’ underperformance relative to its industry peers, Wall Street analysts remain strongly optimistic about the stock’s prospects.

Barchart

Get all your
news in one place.

100's of premium titles.
One news app.

Benzinga

Quest Diagnostics Reports Q3 Earnings, Shares Slide

Shares of Quest Diagnostics (NASDAQ:DGX) are falling Tuesday after the medical laboratories company shared mixed earnings results.

Tom’s Hardware

Jensen Huang personally delivers DGX Spark Mini PCs to Elon Musk and Sam Altman — separately

We spotted both Elon Musk and Sam Altman being handed cute glittering DGX Spark mini PCs by Jensen Huang this week.

Barchart

What to Expect From Quest Diagnostics’ Next Quarterly Earnings Report

Quest Diagnostics is gearing up to announce its third-quarter results in the upcoming week, and analysts expect a notable single-digit growth in earnings.

Barchart

Is Quest Diagnostics Stock Underperforming the Dow?

Although Quest Diagnostics has underperformed the Dow recently, analysts remain moderately optimistic about the stock’s prospects.

Get all your
news in one place.

100's of premium titles.
One news app.

Barchart

Is Waters Stock Underperforming the S&P 500?

Despite Waters’ weak performance relative to the S&P 500 Index over the past year, analysts are moderately optimistic about the stock’s prospects.

Barchart

Are Wall Street Analysts Predicting Quest Diagnostics Stock Will Climb or Sink?

Quest Diagnostics has outperformed the broader market over the past year, and analysts are moderately optimistic about the stock’s prospects.

Benzinga

Options Corner: Quest Diagnostics' Post-Earnings Digestion Drama Opens A Science-Backed Opportunity

Quest Diagnostics Inc (NYSE:DGX) may be encountering what you might call a post-earnings digestion dance. Initially, DGX stock jumped higher, perhaps due to the algorithms and retail traders responding in unison to the better-than-expected results for the second quarter. But the next day, the security slipped, possibly as fund managers…

Benzinga

Quest Diagnostics Raises Outlook, But Warns Of Tariff And Medicare Act Risks

Quest Diagnostics Inc. (NYSE:DGX) delivered a robust second quarter in 2025, exceeding analyst expectations with strong sales and earnings growth, prompting an upward revision to its full-year guidance.

Barchart

Despite Slump, Options Traders May be Seeing Something with Quest Diagnostics (DGX)

While DGX stock has been hammered in the market recently, the smart money may be sensing a bounce-back opportunity.

Barchart

What to Expect From Quest Diagnostics' Q2 2025 Earnings Report

Quest Diagnostics is expected to unveil its second-quarter results later this month, and analysts expect a single-digit growth in earnings.

Barchart

Is Quest Diagnostics Stock Outperforming the Nasdaq?

While Quest Diagnostics has outshined the broader Nasdaq Composite over the past year, Wall Street analysts remain cautiously optimistic about the stock’s prospects.

1 2

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Read news from The Economist, FT, and more,
with one subscription

Topics

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.